EQS-News: Darwin AG Announces Preliminary Group Revenue for 2025 and Confirms Strategic Growth Trajectory
|
EQS-News: Darwin AG
/ Key word(s): Preliminary Results/Development of Sales
Corporate News
Darwin AG Announces Preliminary Group Revenue for 2025 and Confirms Strategic Growth Trajectory Munich, February 25, 2026 – Darwin AG (ISIN DE000A3C35W0) today announces its preliminary consolidated revenue for the 2025 financial year. Based on preliminary financial figures, the company generated consolidated revenue of approximately €55 million in the 2025 financial year (previous year: €25.3 million). This corresponds to revenue growth of approximately 117% compared to the previous year. In addition, the company expects to report a positive consolidated net result. “We are very satisfied with the development of consolidated revenues in the 2025 financial year. The preliminary revenue figures underline the operational strength of our group,” comments CEO Dr. Daniel Wallerstorfer. “With the products of our wholly owned subsidiary Novogenia GmbH, we have gained international visibility for our comprehensive genetic analyses and the personalized nutritional supplements based on them. The strategic partnerships with 10X Health (USA) and M42 (Abu Dhabi) form the foundation for a new phase of scaling. For Darwin AG, we see significant potential for sustainable value creation through the implementation of these major projects and additional initiatives.” The full audited consolidated financial figures for 2025 will be published together with the 2025 Annual Report on May 12, 2026.
About Darwin AG The “Darwin Group” (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European healthcare company, particularly active in the field of human genetics and the development of personalized products based on genetic analysis. The genetic analyses conducted in the company’s own laboratory are used in the diagnosis, treatment, and prevention of diseases, as well as in the production of individually tailored nutritional supplements and cosmetics. Darwin also acts as a partner to physicians, therapists, pharmacists, nutritionists, and fitness trainers, helping to ensure treatment or support that is as optimal as possible for the patient’s or client’s needs by analyzing their respective genetic predispositions. In addition, Darwin holds investments in innovative companies in the biotech, healthcare, and life sciences sectors.
Contact:
25.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2281138 25.02.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 0,00 | 161,76 | 223,81 | 18,17 | 25,29 | 55,00 | 70,00 | |
| EBITDA1,2 | 0,00 | 30,16 | 72,82 | 1,61 | 35,79 | -3,50 | 2,70 | |
| EBITDA-Margin3 | 0,00 | 18,65 | 32,54 | 8,86 | 141,52 | -6,36 | 3,86 | |
| EBIT1,4 | 0,00 | 29,66 | 65,05 | -3,74 | 26,37 | -6,60 | 0,50 | |
| EBIT-Margin5 | 0,00 | 18,34 | 29,07 | -20,58 | 104,27 | -12,00 | 0,71 | |
| Net Profit (Loss)1 | 0,00 | 19,39 | 42,88 | 0,04 | 18,47 | 3,50 | 0,65 | |
| Net-Margin6 | 0,00 | 11,99 | 19,16 | 0,23 | 73,03 | 6,36 | 0,93 | |
| Cashflow1,7 | 0,00 | 10,39 | 95,15 | -18,95 | -24,89 | -6,00 | -1,50 | |
| Earnings per share8 | 0,00 | 1,62 | 3,76 | 0,01 | 1,54 | 0,29 | 0,05 | |
| Dividend per share8 | 0,00 | 0,44 | 1,75 | 0,56 | 0,56 | 0,56 | 0,56 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Treuhandgesellschaft Südbayern
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Darwin | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3C35W | DE000A3C35W0 | AG | 106,80 Mio € | 02.11.2021 | Kaufen | 8FWH4HVG+4F |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 17,80 | 9,42 | 1,89 | 16,18 | 1,10 | -4,29 | 1,94 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,56 | 0,56 | 0,56 | 6,96% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.06.2026 | 15.10.2025 | 05.12.2025 | 12.05.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +0,09% | +16,63% | +4,55% | +8,05% | +13,38% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
